Given that anti-TIGIT monotherapy has generally shown limited efficacy, while combinations with anti-PD-(L)1 perform better in several settings, our data support the rationale for exploring TIGIT blockade as an add-on strategy, potentially with greatest value in MSI and/or BRAF-mutant CRC, where TIGIT/CD155 expression could be significantly upregulated. This evidence concerns the gene CD274 and colorectal carcinoma.